Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Menarini-Group"

7 News Found

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
News | January 07, 2024

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.


Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Drug Approval | June 23, 2022

Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients


Menarini strengthens its presence in aesthetic dermatology in India
News | September 30, 2023

Menarini strengthens its presence in aesthetic dermatology in India

The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation


European Medicines Agency accepts Menarini’s application for Elacestrant
Drug Approval | August 20, 2022

European Medicines Agency accepts Menarini’s application for Elacestrant

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union


A.Menarini expands its dermatology portfolio with the launch of Solar D
Healthcare | May 27, 2022

A.Menarini expands its dermatology portfolio with the launch of Solar D

The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D


Glenmark receives marketing approval for Ryaltris in 13 countries across the EU and UK
Drug Approval | September 30, 2021

Glenmark receives marketing approval for Ryaltris in 13 countries across the EU and UK

Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis


Glenmark’s Ryaltris nasal spray approved in Europe
News | April 27, 2021

Glenmark’s Ryaltris nasal spray approved in Europe

In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark